Biolinerx ( Biolinerx)

Primary tabs

Biolinerx's picture

Management

Contact Address

About Biolinerx

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

Biolinerx press release, blog etc

Tue, 01/18/2022 - 02:16 BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients
Fri, 12/17/2021 - 02:06 BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
Wed, 12/15/2021 - 00:40 BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)
Tue, 10/12/2021 - 23:50 BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
Tue, 05/04/2021 - 13:47 BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients
Thu, 04/15/2021 - 13:03 BioLineRx Announces Presentation at 2021 American Association for Cancer Research (AACR) Annual Meeting
Mon, 09/23/2019 - 07:10 Pushing Boundaries with Lakey Peterson
Mon, 07/29/2019 - 03:54 hospitals in Westwood and Santa Monica ranked No. 1 in Los Angeles, No. 1 in California and No. 6 nationally in the 201920 assessment published today by U.S. News & World Report.
Tue, 07/02/2019 - 10:22 Toyota Motor North America Reports U.S. Sales for June, First Half of 2019
Tue, 05/14/2019 - 08:58 On track for Phase 2 data read-outs in pancreatic cancer and
Tue, 05/07/2019 - 07:30 Phase 1/2a study ongoing in the UK and Israel, with sites in the US expected to join by H1 2020
Thu, 03/28/2019 - 07:48 BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months
Tue, 03/26/2019 - 23:15 Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation
Thu, 03/21/2019 - 16:21 BioLineRx to Report Annual 2018 Results on March 28, 2019
Thu, 03/21/2019 - 00:34 Management to hold a conference call at 10:00 a.m. EDT
Thu, 03/14/2019 - 00:13 BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
Mon, 02/04/2019 - 04:13 BioLineRx Receives Orphan Drug Designation from the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Wed, 01/02/2019 - 03:55 BioLineRx to Present at the 2019 Biotech Showcase
more

InfoBox

HomePagewww.biolinerx.com
Twittertwitter.com/biolinerx_ltd
LinkedInwww.linkedin.com/company/biolinerx
Wikipediaen.wikipedia.org/wiki/BioLineRx